This further exploration could be useful for cancers like pancreatic, bladder, and breast cancer, which have all been treated concurrently with anti-PD-1 and a CCR2 antagonist (Orth et al., 2019; Tu et al., 2020). This evidence concerns the gene CCR2 and breast carcinoma.